1996
DOI: 10.1016/s0065-7743(08)60459-5
|View full text |Cite
|
Sign up to set email alerts
|

Chapter 20. Cell Adhesion Integrins as Pharmaceutical Targets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

1998
1998
2011
2011

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(8 citation statements)
references
References 112 publications
0
8
0
Order By: Relevance
“…This work used conformationally constrained cyclic peptides bearing a similar small binding motif to inform the design of small molecule leads that had remarkably high selectivity for closely related integrin receptor subtypes (Engleman et al, 1996;Samanen, 1996;Samanen et al, 1996;Keenan et al, 1997).…”
Section: E the Need For More G Protein-coupled Receptor Structural Workmentioning
confidence: 99%
“…This work used conformationally constrained cyclic peptides bearing a similar small binding motif to inform the design of small molecule leads that had remarkably high selectivity for closely related integrin receptor subtypes (Engleman et al, 1996;Samanen, 1996;Samanen et al, 1996;Keenan et al, 1997).…”
Section: E the Need For More G Protein-coupled Receptor Structural Workmentioning
confidence: 99%
“…BALB/c-3T3 cell adhesion and spreading on surface-immobilized dextran, RGD peptide-grafted dextran, and RGD peptide mimetic-grafted substrates. AAGPAHA and GRGDSP peptide were covalently immobilized on dextran-coated tissue culture plastic utilizing methods that we have developed for cell adhesion peptides [15][16][17]. All data are expressed as a percentage of control adhesion on uncoated tissue culture plastic.…”
Section: Stability Of Aagpaha and Grgdsp In Solutionmentioning
confidence: 99%
“…Candidate reagents for biotherapeutic applications include monoclonal antibodies, RGD peptides, and peptidomimetics that block integrin function [15]. Peptidomimetics are of particular interest for therapeutic applications because they have low immunogenicity and are resistant to protease/peptidase-mediated degradation [15]. The major disadvantage to peptidomimetics is that they are typically difficult to synthesize requiring lengthy organic syntheses of precursors.…”
Section: Introductionmentioning
confidence: 99%
“…[2e] In the development of organotin acylation catalysts, [2g,h, 3] we have established that they are so mild that various selective acylation reactions are feasible but their acidity is not strong enough to perform acylation of sterically hindered alcohols. In this context, we were intrigued to employ bismuth triflate Bi(OTf) 3 [4] since it had proved to be easy to handle due to its stability in the air and to be acidic enough to catalyze Friedel ± Crafts, [5] Diels ± Alder, [6] and ene reactions. [7] As shown in Table 1, Bi(OTf) 3 can promote the acetylation of primary, secondary, and tertiary alcohols in acetic anhydride at 25 8C [Eq.…”
Section: As Catalystmentioning
confidence: 99%
“…The b 3 class of the integrin family, a IIb b 3 (GPIIb/IIIa or fibrinogen receptor) and a V b 3 (vitronectin receptor), has received special attention in recent drug research. [4,5] a IIb b 3 is prevalent on platelets and plays a role in thromboembolic disorders, [5] while a V b 3 is the dominant receptor for mediating the attachment of osteoclasts to bone during bone resorption [6,7] and has been implicated in tumor progression, angiogenesis, [5,8,9] and restenosis. [10] Many integrins, including a IIb b 3 and a V b 3 , interact with a common Arg-Gly-Asp (RGD) binding motif in their target proteins.…”
mentioning
confidence: 99%